Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Global X Copper Miners ETF (COPX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Global X Copper Miners ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.91 (market cap $29.60B), while Global X Copper Miners ETF trades at $88.63. The key difference: Global X Copper Miners ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | COPX | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $491.22 | $95.70 |
52-Week Low | $205.48 | $46.08 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
COPX (Global X Copper Miners ETF) trades at $88.51, down 1.12% today, while maintaining a bullish technical outlook with strong moving average signals. The ETF offers exposure to copper miners benefiting from AI-driven demand for electrification infrastructure. Recent institutional buying includes 180 Wealth Advisors increasing its position by 28.1% in Q2 2026 (SEC filing, August 2026). Technical indicators show overbought RSI levels but strong trend momentum with ADX readings.
The copper mining sector faces structural demand growth from AI data center expansion and electrification trends, though mining equities currently trade at a discount to copper futures. Supply constraints and cyclical volatility present risks, but analyst sentiment remains positive for long-term exposure to copper's role in the energy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →
